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• Tumor rupture is the strongest predictive factor for AGCT recurrence.
• AGCT requires active follow up for ten to ﬁfteen years after primary diagnosis.
• Recurrences may develop asymptomatically and in multiple anatomical locations.
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Available online 10 October 2016Objective. Adult-type ovarian granulosa cell tumors (AGCTs) have an unpredictable tendency to relapse. In a
carefully validated patient cohort, we evaluated the prognostic factors related to AGCT recurrence.
Methods. We identiﬁed all patients diagnosed with AGCT during 1956–2014 in Helsinki University Hospital,
with a minimum follow-up of one year (n = 240). After a histological review supplemented with FOXL2 (402C-
G) mutation status analysis, we analyzed the clinical data for association with relapse.
Results. The ﬁnal cohort included 164 (68%) molecularly deﬁned AGCTs (MD-AGCTs). The majority of the
women were postmenopausal (63%), and 92% of tumors were stage I. The median follow-up time was 15.5 years.
Fifty-two (32%) patients developed tumor recurrence, ofwhom55%had successive recurrences.Multiple-site recur-
rences were common, and nearly half of the recurrences were asymptomatic. The median time to the ﬁrst relapse
was 7.4 years, and 75% of relapses occurred within ten years after primary diagnosis. The median disease-free sur-
vival was 11.3 years. Premenopausal status at initial diagnosis, FIGO stage Ic versus Ia, and tumor rupture associated
with relapse. However, tumor rupturewas the only independent predictive factor. Of the relapsed patients, 48%died
of AGCT in a median time of 15.3 years.
Conclusion.Tumor rupture is the strongest predictive factor for recurrence, and these patientsmight beneﬁt from
a more aggressive initial treatment approach. AGCT requires active follow up for 10 to 15 years after primary diag-
nosis, since recurrences may develop late, asymptomatically and in multiple anatomical locations.




Adult-type granulosa cell tumors (AGCTs) represent a rare form of
ovarian cancer characterized by a single somatic point mutation in the
transcription factor FOXL2 [1–3]. Despite the indolent disease course
and relatively favorable prognosis, AGCTs exhibit an unpredictablegy, University of Helsinki and
Finland.tendency to late relapse [4–9]. Previous studies have shown that up to
one-third of patients with AGCT develop tumor recurrence, even in
early stage disease, leading to increasedmortality [8,10]. The only clinical
factor consistently related to prognosis is tumor stage [4,5,10–15]. Tumor
size, tumor rupture, presence of residual tumor, incomplete staging, and
even bodymass index and diabetes have been suggested as clinical prog-
nostic factors for recurrence [9,10,15–19]. Histopathologic and molecular
prognosticators have included nuclear atypia, mitotic rate, diffuse growth
pattern and expression of transcription factor GATA4 and human epider-
mal growth factor receptor HER2 [12,13,18,20,21]. Most of these studies
572 S. Bryk et al. / Gynecologic Oncology 143 (2016) 571–577have, nonetheless, lacked the diagnostic validation of tumors with FOXL2
mutation status and suffered from either small number of patients or rel-
atively short follow-up periods [4,14,16,19,20].
As disease relapse accounts for the majority of tumor related mor-
bidity andmortality, themost important challenges in themanagement
of AGCT patients lie in the identiﬁcation andmanagement of patients at
increased risk for relapse. Furthermore, speciﬁc guidelines as to how
these patients should be followed and treated upon relapse have not
been established. The routine follow-up time varies from 2 to 5 years
or even beyond 5 years as recommended by the National Comprehen-
sive Cancer Network (NCCN) and European Society for Medical Oncolo-
gy (ESMO) [22,23]. The aim of the present study was to analyze the
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Fig. 1.Ahistological review supplementedwith FOXL2 (402C-G)mutation status analysiswas p
resulting in a patient cohort of molecularly deﬁned AGCTs (MD-AGCTs, n= 164). Altogether, 76
the relapsed patients died of AGCT. Two patients were lost to follow-up during the study period
ca = carcinoma, FATWO= female adnexal tumor of probable Wolfﬁan origin.recurrence, and to identify an optimal follow-up pattern for these pa-
tients, using a large, histologically and molecularly validated single-in-
stitute, population-based patient cohort.
2. Materials and methods
The ethics committee of Helsinki University Hospital (HUH) and the
National Supervisory Authority for Welfare and Health approved the
study. All patients diagnosed with GCT during 1956–2014 in HUH were
identiﬁed, with a minimum follow-up of one year. A histological review
supplemented with immunohistochemical staining was performed on
all original slides to conﬁrm the diagnosis, and each case underwent
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erformed on all patients initially diagnosedwith adult-type granulosa cell tumors (AGCTs),
patients were excluded from the study. Fifty-two patients (32%) relapsed, and 25 (48%) of
, each over 15 years after primary diagnosis. SCAT= sex cord tumorwith annular tubules,
Table 2
Primary tumor and treatment characteristics of molecularly deﬁned adult granulosa cell










573S. Bryk et al. / Gynecologic Oncology 143 (2016) 571–577molecularly deﬁned adult-type granulosa cell tumors (MD-AGCTs). De-
tails of the FOXL2 analysis have been described in a recent publication
[3]. Patientswho lacked either histological sample or FOXL2mutation sta-
tus were excluded from the analysis (Fig. 1).
Clinical characteristics were obtained from the patient medical re-
cords and included age, menopausal status, parity, use of hormonal treat-
ment and initial symptoms, tumor size, stage, treatment and follow-up
regarding both primary and recurrent tumors. Tumor stage was based
on the International Federation of Gynecology and Obstetrics (FIGO)
criteria [24]. The follow-up information included details on follow-up
visits performed at HUH or other units, recurrences, and survival. Survival
data were obtained from the Finnish Population Register on Sep 14th
2015, and from death certiﬁcates including diagnoses of the cause of
death from the Statistics Finland. The clinical data were collected into a
database using FileMaker Pro 11.0v4 (FileMaker, Inc., Santa Clara, CA,
USA).
The clinical characteristicswere evaluated for associationwith relapse.
Disease-free survival was deﬁned as the time period from the date of pri-
mary diagnosis to the ﬁrst conﬁrmed recurrence or last follow-up. Recur-
rence was recorded only in patients proven tumor-free after initial
treatment, i.e. having no residual tumor after surgery or chemotherapy,
the latter dependent upon a clean CT scan or second-look operation.
This principle was also applied when deﬁning successive recurrences in
a single patient. Recurrence sites were grouped in anatomical regions,
and recurrence was considered multiple when two or more tumors
were simultaneously detected in more than one anatomical region. The
year of diagnosis was grouped in two categories (1956–1983 and 1984–
2014), mainly based on major developments in imaging (CT-scan andTable 1
Clinical characteristics of molecularly deﬁned adult granulosa cell tumor (MD-AGCT) pa-










Year of diagnosis ns
1956–1983 59 (36.0%) 35 (32.4%) 22 (42.3%)






55.6 (27–81) 49.9 (26–80) 0.046
b50 58 (35.4%) 31 (28.7%) 26 (50.0%) 0.008
N50 106 (64.6%) 77 (71.3%) 26 (50.0%)
Menopause 0.004
No 59 (36.6%) 31 (29.2%) 27 (52.9%)
Yes 102 (63.4%) 75 (70.8%) 24 (47.1%)
Parity ns
Nulliparous 56 (34.6%) 38 (35.5%) 16 (31.4%)
Primiparous 37 (22.8%) 20 (18.7%) 17 (33.3%)
Multiparous 69 (42.6%) 49 (45.8%) 18 (35.3%)
Infertility ns
Yes 27 (17.3%) 20 (19.4%) 7 (14.3%)
No 129 (82.7%) 83 (80.6%) 42 (85.7%)
Oral contraceptives1 ns
Yes 54 (43.9%) 40 (47.1%) 14 (40.0%)
No 69 (56.1%) 45 (52.9%) 21 (60.0%)
Initial symptoms ns
Abnormal bleeding 76 (46.6%) 52 (48.2%) 22 (43.1%)
Abdominal pain 41 (25.2%) 25 (23.1%) 14 (27.5%)
Abdominal
distension
21 (12.9%) 12 (11.1%) 9 (17.6%)
General symptoms 1 (0.6%) 1 (0.9%) 0 (0.0%)
Asymptomatic 24 (14.7%) 18 (16.7%) 6 (11.8%)
Preoperative HRT ns
Yes 24 (20.0%) 16 (18.6%) 8 (25.8%)
No 96 (80.0%) 70 (81.4%) 23 (74.2%)
Postoperative HRT ns
Yes 47 (49.0%) 34 (47.9%) 13 (52.0%)
No 49 (51.0%) 37 (52.1%) 12 (48.0%)
⁎Of those documented (lost to follow-up n = 2, not free of disease n = 2), ns = not sig-
niﬁcant, 1before and after diagnosis, HRT = hormone replacement therapy.pelvic ultrasound), surgery and introduction of platinum-based chemo-
therapy [11].
Statistical analysis was performed using JMP Pro 10.0.2 (SAS Insti-
tute Inc., Cary, NC, USA). Pearson's Chi-Square Test and Fisher's exact
test were used to test associations between groups. Continuous vari-
ables were analyzed for normal distribution with the Shapiro-Wilks
test and compared with non-parametric test (Mann-Whitney). The dis-
ease-free survival curveswere obtainedusing theKaplan-Meiermethod
andwere compared using the log-rank test. Univariate andmultivariate
analyses were conducted using Cox's regression model. A p-value of
b0.05 was considered statistically signiﬁcant.
3. Results
3.1. Primary tumor characteristics and follow-up
After histological and molecular evaluation, 164 of the 240 women
(68%) were included in the ﬁnal analysis (Fig. 1). Mean follow-up time
was 16.8 years (median 15.5 years; range 1.0–51.3 years). Patient and
tumor characteristics at the time of primary diagnosis are described in de-
tail in Table 1 and Table 2. The mean time in completed hospital-basedTumor size
Mean (range), cm 10.9
(0.5–30)
10.4 11.7 ns
b10 cm 74 (47.4%) 53 (51.0%) 21 (43.8%) ns
≥10 cm 82 (52.6%) 51 (49.0%) 27 (56.2%)
Tumor ruptureb 0.005
Yes 56 (35.7%) 29 (28.2%) 26 (51.0%)
No 101 (64.3%) 74 (71.8%) 25 (49.0%)
Ascites ns
Yes 33 (22.9%) 21 (21.4%) 12 (27.9%)
No 111 (77.1%) 77 (78.6%) 31 (72.1%)
FIGO stage ns
I 148 (91.9%) 100 (93.5%) 46 (90.2%)
II 10 (6.2%) 6 (5.6%) 3 (5.9%)
III 3 (1.9%) 1 (0.9%) 2 (3.9%)
Surgical approach
Laparoscopy 31 (18.9%) 21 (19.4%) 10 (19.2%) ns
Laparotomy 133 (81.1%) 87 (80.6%) 42 (80.8%)
Surgery ns
Completec 128 (78.5%) 90 (83.3%) 37 (71.2%)
Incomplete 35 (21.5%) 18 (16.7%) 15 (28.8%)
Stagingd 0.002
Yes 48 (29.8%) 41 (38.3%) 7 (13.7%)
No 113 (70.2%) 66 (61.7%) 44 (86.3%)
Lymphadenectomy 0.047
Yes 37 (23.0%) 30 (28.0%) 7 (13.7. %)




Yes 28 (17.2%) 20 (18.5%) 8 (15.7%)
No 135 (82.8%) 88 (81.5%) 43 (84.3%)
Tumor histology ns
Follicular/trabeculoid 53 (37.9%) 39 (40.6%) 12 (30.0%)
Diffuse/sarcomatoid 87 (62.1%) 57 (59.4%) 28 (70.0%)
Endometrial pathology ns
Normal 52 (38.0%) 37 (37.8%) 13 (37.1%)
Polyps 18 (13.1%) 12 (12.2%) 6 (17.1%)
Hyperplasia 57 (41.6%) 39 (39.8%) 16 (45.7%)
Carcinoma 10 (7.3%) 10 (10.2%) 0 (0.0%)
a Of those documented (lost to follow-up n = 2, not free of disease n = 2), ns = not
signiﬁcant.
b Stage IC1, n = 32, stage IC2, n = 18, stage II n = 5, stage III n = 1), FIGO=
International Federation of Gynecology and Obstetrics.
c No gynecological organs left.
d Peritoneal biopsies and omental biopsy or omentectomy.
C. Tumor rupture
B. Stage Ia vs Ic
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Fig. 2. Kaplan-Meier curves of disease-free survival according to A) menopausal status B)
stage Ia versus Ic, and C) tumor rupture.
574 S. Bryk et al. / Gynecologic Oncology 143 (2016) 571–577routine follow-up was 5.5 years for all patients after primary treatment,
and 6.2 and 5.4 years for patients with andwithout tumor recurrence, re-
spectively (p = 0.3). The median number of hospital visits was 11.
Transabdominal or transvaginal pelvic ultrasound was performed at
least once in routine follow-up on 97 patients (68% of those with data
available) and a CT-scan on 41 patients (28%). PET/CT was used nine
times, most often unsuccessfully. Serum markers were measured in 101
(71%) patients, and consisted of e.g. estradiol (E2), carcinoembryonic an-
tigen (CEA), CA-125, Inhibin B, and anti-Müllerian hormone (AMH). Rou-
tine monitoring for Inhibin B and AMH levels began in 1998 and 2014,
respectively, and in primary follow-up either one was measured in alto-
gether 70 patients.
3.2. Relapse
Fifty-two of the 164 patients relapsed, resulting in a recurrence rate
of 32.1% (Fig. 1). One relapse was observed in 23 patients, two relapses
in 17 patients, three in ﬁve patients, four in four patients, ﬁve in two pa-
tients, and six in one patient. The median time to the ﬁrst relapse was
7.4 years (range 1.1–26.6 years), and the median time between the
ﬁrst and second relapse was 2.9 years (range 0.7–29.6), and the second
and third 1.4 years (range 0.7–4.4 years). The majority of ﬁrst relapses
(75%) occurred within ten years, and 87% within 15 years after primary
diagnosis (Supplementary Fig. S1).
When evaluating the primary clinical characteristics of patients ac-
cording to relapse, we found a signiﬁcantly higher rate of relapses
among premenopausal patients (47% vs. 24%, p = 0.004). Age distribu-
tion differed between the relapsed and non-relapsed groups both as a
categorical (≷ 50 years) and continuous variable, where younger age as-
sociated with increased rate of relapses. Tumor rupture, including both
perioperative (stage IC1, n=32, stage II n=3), and spontaneous (stage
IC2, n= 18, stage II n= 2, stage III n= 1) ruptures, wasmore common
in the recurrent group (51% vs. 28%, p = 0.005), as was the lack of stag-
ing surgery and lymphadenectomy (p = 0.002 and p = 0.047, respec-
tively) (Table 2). In routine follow-up, serummarkers were monitored
and ultrasound performed more often among non-recurrent patients.
However, the year of diagnosis as such had no signiﬁcant impact on re-
currence rate (Table 1). In a subanalysis including only stage IC tumors
(n = 53), we found that the lack of staging surgery and lymphadenec-
tomywere signiﬁcantlymore common among patients with recurrence
(Supplementary Table S1).
In Kaplan-Meier and Cox's univariate analyses, the risk of relapse
was increased in premenopausal patients, FIGO stage IC versus IA tu-
mors, and in patients with tumor rupture (Fig. 2). The risk was also sig-
niﬁcantly increased in both stage IC1 and stage 1C2 subgroups alone,
when compared with stage 1 A tumors. Premenopausal status was sig-
niﬁcant by 15 years (p = 0.04) and 20 years (p = 0.02) of follow-up,
whereas stage IC and tumor rupture were signiﬁcant predictors already
byﬁve years of follow-up (p=0.02 and 0.03, respectively). Inmultivar-
iate analysis, tumor rupturewas the only signiﬁcant risk factor for AGCT
recurrence. In stage IC patients, lack of staging surgery and adjuvant
chemotherapy were associated with recurrence in univariate analysis.
However, in multivariate analysis neither of these was an independent
risk factor. When further evaluating the risk for successive relapses
after the ﬁrst recurrence, tumor rupture at the time of recurrence was
the only signiﬁcant clinical risk factor for second relapse.
3.3. Recurrent tumor characteristics
The characteristics of recurrent tumors are presented in Table 3. Re-
currences were asymptomatic in 38% of ﬁrst events of relapse, and in
the majority (57–62%) of the successive relapses. Forty-ﬁve percent of
all asymptomatic tumors were local recurrences in the pelvis. When
symptomatic, all recurrences presented most often with abdominal
pain. Other, signiﬁcantly less common symptoms included menstrual
cycle disturbances, a palpable mass and abdominal bloating. Thirty-eight percent of ﬁrst relapses were discovered by clinical examination
alone or in combination with vaginal ultrasound and/or serum markers.
Serum marker levels were measured from 64% patients at ﬁrst relapse,
and from 73% of patients at all relapses combined. When measured, CA-
Table 3
Characteristics of molecularly deﬁned adult granulosa cell tumor patients (n = 164), ac-








1956–1983 15 (28.8%) 4 (13.8%) 1 (4.3%)
1984–2014 37 (71.2%) 25 (86.2%) 22 (95.7%)
Age
b50 15 (28.8%) 8 (27.6%) 4 (17.4%)
N50 37 (71.2%) 21 (72.4%) 19 (82.6%)
Menopause
No 10 (19.2%) 1 (3.4%) 0 (0.0%)
Yes 42 (80.8%) 28 (96.6%) 23 (100.0%)
Gynecological organs leftb
Yes 15 (28.8%) 3 (10.3%) 0 (0.0%)
No 37 (71.2%) 26 (89.7%) 23 (100.0%)
Symptoms
Yes 30 (62.5%) 11 (37.9%) 9 (42.9%)
No 18 (37.5%) 18 (62.1%) 12 (57.1%)
Ca12-5
Elevated 8 (33.3%) 5 (27.8%) 3 (42.9%)
Normal 16 (66.7%) 13 (72.2%) 4 (57.1%)
Inhibin-B
Elevated 16 (88.9%) 17 (94.4%) 12 (100.0%)
Normal 2 (11.1%) 1 (5.6%) 0 (0.0%)
Tumor size (mass)
b10 cm 22 (45.8%) 18 (62.1%) 10 (45.5%)
≥10 cm 26 (54.2%) 11 (37.9%) 12 (54.5%)
Ascites
Yes 10 (25.0%) 4 (14.3%) 5 (26.3%)
No 30 (75.0%) 24 (85.7%) 14 (73.7%)
Tumor rupturec
Yes 16 (39.0%) 4 (14.8%) 6 (28.6%)
No 25 (61.0%) 23 (85.2%) 15 (71.4%)
Treatment
Radical surgery 19 (36.5%) 11 (37.9%) 6 (26.1%)
Surgery + adjuvantd 24 (46.2%) 6 (20.7%) 7 (30.4%)
Palliative surgery 2 (3.8%) 1 (3.5%) 1 (4.4%)
CT 3 (5.8%) 3 (10.3%) 4 (17.4%)
CT + othere 1 (1.9%) 3 (10.3%) 0 (0.0%)
CT + radiotherapy 0 (0.0%) 1 (3.5%) 0 (0.0%)
Radiotherapy 0 (0.0%) 1 (3.5%) 0 (0.0%)
Aromatase inhibitor 0 (0.0%) 0 (0.0%) 2 (8.7%)
No treatment 3 (5.8%) 3 (10.3%) 3 (13.0%)
a III n = 5, IV n = 4, V n = 2, VI n = 1.
b Uterus or ovary.
c Spontaneus or intraoperative.
d Chemo- or radiotherapy, CT = chemotherapy.
e Aromatase inhibitor n = 4, bevasizumab n = 2.
575S. Bryk et al. / Gynecologic Oncology 143 (2016) 571–577125was elevated in 33% of relapses (in 28% of pelvic, 36% of multiple and
40% of abdominal tumors), and Inhibin-B in 94% of relapses. The clinical
use of AMH had only recently been established, and was measured in
three patients, showing elevated levels prior to relapse in all cases.
Anatomical sites of recurrence are presented in Fig. 3.Majority of the
single recurrences occurred in the pelvis. The secondmost common sin-
gle-tumor site was abdominal cavity excluding pelvis, both for ﬁrst and
successive relapses. However, multiple-site recurrence was observed in
nearly half of all events of relapse, the proportion remaining similar
from 1st to 6th relapses (39–44%). Of all sites, the pelvis was most
often involved also in multiple-site recurrence through successive re-
lapses, and the proportion was highest at ﬁrst relapse (45%). Other
sites included the retroperitoneum, liver, inguinal, mediastinal or
para-aortic lymph nodes, abdominal wall, lung, and bone (iliac bone,
pelvic and thoracic spine). Recurrences in the abdominal wall were
seen after both laparotomy (n = 6) and laparoscopy (n = 3).
The majority (70%) of recurrences were treated by surgery with or
without adjuvant chemotherapy or radiotherapy (Table 3). Radical sur-
gery with no macroscopic evidence of disease was achieved in 37% of
ﬁrst and 26% of 3rd to 6th recurrences. Ten cases received chemothera-
py alone, four cases chemotherapy combined with aromatase inhibitor
(letrozole) and/or angiogenesis inhibitor (bevacizumab) and in onecase, chemotherapywas used in combinationwith radiation. Radiother-
apy alone was given to one patient with a single recurrent tumor, and
hormonal treatment (letrozole) alone to two cases. Four cases
underwent palliative surgery, and nine tumors were left untreated
due to patient will, old age or poor medical condition.
3.4. Survival and outcomes
In the whole cohort, the ﬁve- and ten-year overall survival rates were
96.3% and 88.4%, and disease-speciﬁc survival rates 98.7% and 93.5%, re-
spectively. The median overall survival among non-recurrent patients
was 30.6 years and among recurrent patients 26.5 years (p = 0.03).
Outcomes are presented in Fig. 1. Twenty-seven patients died of
AGCT during follow-up. Median disease-free survival (DFS) was
11.3 years. After the ﬁrst recurrence, median DFS was 3.5 years, and
overall survival 8.0 years. A total of six patients have remained dis-
ease-free after the ﬁrst recurrence with a median follow-up of
7.7 years. Nearly half (48%) of the relapsed patients died of AGCT, in a
median time of 15.3 years. The proportion of disease-related death
was 52% among patients with one recurrence, 31% among those with
two, 67% among those with three, 75% among those with four, and
100% among those with ﬁve to six recurrences. There was no signiﬁcant
difference inmedian disease-free survival between patients with one or
several successive relapses (7.6 vs. 7.0 years, respectively).
4. Discussion
We have herein studied thus far the largest cohort of FOXL2 (402C-
G) mutation validated granulosa cell tumor patients treated in a single,
population-based institute during a six-decade-long period in order to
identify reliable risk factors and the clinical picture of tumor recurrence,
and guidelines for clinical follow-up. To our knowledge, this is themost
comprehensive study to date in analyzing the clinical characteristics of
AGCT recurrence. Given the rarity and diagnostic challenges of AGCTs
together with the tendency to late recurrences, studies on its clinical
course require standardized diagnostics accompanied with decades of
follow-up. The molecular diagnostics has been proven crucial in differ-
entiating AGCTs from other, usually more malignant ovarian tumors
with signiﬁcantly worse prognosis [3]. Therefore, the determination of
FOXL2 mutation status is recommended in the primary diagnostics of
AGCT [3,25]. Prior studies focusing on AGCT recurrence have, however,
lacked the diagnostic accuracy achieved with molecular validation. The
32% recurrence rate with a median time-to-relapse of 7.4 years in this
study represents a slightly higher rate and longermedian time than ob-
served in most prior works, where recurrence rates vary signiﬁcantly
from 5% to 64% [18,20], althoughmost studies with large patients series,
extensive follow-up and tertiary-center treatment have documented a
recurrence rate of 20–30% [9,17,26].
Upon relapse, AGCT showed an aggressive course: more than half of
the relapsed patients had more than one event of disease recurrence,
and nearly half of the relapsed patients eventually died of AGCT. In pa-
tients with more than one relapse, the pattern of recurrence resembles
that of epithelial ovarian cancer, where the median time to the follow-
ing relapse shortens by half along with each new recurrence. However,
the median survival times of over 25 years among both non-recurrent
and recurrent patients reﬂect the slow and indolent course of AGCT.
We found tumor rupture and stage IC, including both IC1 and IC2, as
signiﬁcant risk factors for recurrence in the patient cohort with mostly
stage I tumors, similarly to a recent study [9]. In our cohort, the vast ma-
jority of these patients were primarily treated by surgery alone, which is
also the current treatment protocol for all stage I AGCTs at HUH. In a
subanalysis of stage IC patients signiﬁcantly more recurrences occurred
in patients lacking staging surgery or adjuvant chemotherapy. Additional-
ly, tumor rupture at ﬁrst recurrence predicted successive relapses. This
suggests that patients with tumor rupture might beneﬁt from complete
staging including lymphadenectomy, and adjuvant chemotherapy,
  Lung
1. recurrence n=1 (2)
2. recurrence n=1 (2)
3.-6. recurrence n=0 (1)
    Liver
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Fig. 3. Sites of recurrent, molecularly deﬁned adult granulosa cell tumors (MD-AGCTs) in 52 patients and 104 events of relapse, by anatomical region and order of recurrence. Multiple
tumors simultaneously evident in several anatomical regions were present in 44 cases of relapse, and the sites involved are presented in parentheses. The site of recurrence was
unknown in one case.
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chemotherapeutic regimens include BEP, which is the recommended
ﬁrst-line chemotherapy for stages II–IV granulosa cell tumors [22,23]. Al-
ternatively, a combination of paclitaxel-carboplatin may be used [22,23,
27]. Staging surgery was only performed on one-third of patients in our
whole series, reﬂecting both the wide treatment era and the unpredict-
able diagnosis ofmalignant AGCT. This again highlights the need for accu-
rate diagnostics at presentation.
Younger age as well as premenopausal status at the time of primary
diagnosis increased the risk for recurrence. This raises the question
whether these premenopausal patients, often treated with sparing sur-
gery, should eventually undergo radical surgery when pregnancy is no
longer desired, or latest atmenopause. On theother hand, fertility-sparing
or incomplete surgery as suchwas not a risk factor for recurrence, nor for
AGCT-related death in a previous study based on virtually the same pa-
tient cohort [11]. Moreover, laparoscopy as a primary procedure did not
increase the risk for relapse.
The median time to relapse of over seven years calls for long-lasting
follow-up - at least ten to ﬁfteen years from primary diagnosis, includ-
ing regular testing for Inhibin B and/or AMH [28]. Since a signiﬁcant pro-
portion of patients were asymptomatic at relapse, a clinical follow-up
based on symptoms only cannot be recommended. AGCT relapses
show variety in both recurrence sites and symptoms, although local re-
currences in the pelvis are most common, also at multiple-site recur-
rence. Hence, pelvic ultrasound remains a standard follow-up tool but
a CT-scan is recommended in case of suspected relapse – especially
after theﬁrst recurrence,when the proportion of asymptomatic and dis-
tant tumors increases. AGCTs have a low 18-F-ﬂuorodeoxyglucose
(FDG) avidity, and PET/CT is not indicated in the diagnostics and routine
follow-up of these tumors, which was also evident in our data [29,30].
Interestingly, hormone replacement therapy after primary diagnosis
was given to nearly half of the patients. It had no deteriorating effect onprognosis, instead there was a trend for risk reduction in univariate anal-
ysis (data not shown). This is a useful message especially for premeno-
pausal patients, who might suffer from menopausal symptoms after
radical surgery. Based on this evidence, there is no need to limit postmen-
opausal hormone therapy use among patients with a treated AGCT.
The long follow-up period of nearly 60 years is both a strength and a
weakness of this study. Themedian follow-up of 15.5 years (186months)
is the longest reported, and provides reliable data on late-recurring
AGCTs. However, this also results in inconsistency in diagnostic and treat-
mentmodalities, depending on the treatment era, although the year of di-
agnosis as such had no signiﬁcant impact on observed recurrence rates.
Nevertheless all cases underwent molecular and histological validation,
and thus represent accurately diagnosed AGCTs.
In conclusion, we found that tumor rupture was the strongest pre-
dictive factor for recurrence in a large patient cohort with molecularly
validated AGCTs. In case of suspected recurrence, CT scan is recom-
mended since multiple and distant recurrences may occur. Premeno-
pausal patients run an increased risk for relapse, and might beneﬁt
from eventual radical surgery. The role of adjuvant therapy for stage Ic
patients remains to be established, but in the light of the present
study, a more aggressive approach might be needed. The relatively
high and late recurrence rate conﬁrms that AGCT requires active fol-
low-up of ten to ﬁfteen years after primary diagnosis, complemented
with regular monitoring with speciﬁc serummarkers.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygyno.2016.10.002.
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